


Nasal High Flow for Infants and Children

A global overview of current
literature and practice.



Mechanisms of action



NHF definition:¹⁻³

Nasal high flow (NHF) is a mode of noninvasive respiratory support that delivers high flows of heated and humidified blended air and oxygen through an unsealed nasal interface.

NHF benefits:

NHF offers a range of benefits compared with standard oxygen therapy, and there are several mechanisms of action associated with this therapy, including airway hydration and washout of anatomical dead space.

1. Wilkinson et al. Cochrane Database Sys Rev (2016).

2. Collins et al. J Pediatr (2013).

3. Franklin et al. N Engl J Med (2018).

4. de Klerk A. Adv Neonatal Care 8, 98-106 (2008).

5. Saslow J et al. J Perinatol 26, 476-480 (2006).

6. Milési C et al. Intensive Care Med 39, 1088-1094 (2013).


7. Hough J et al. Pediatr Crit Care Med 15, e214-9 (2014).

8. Sinha I et al. Chest 148, 810-823 (2015).

9. Collins CL et al. Eur J Pediatr 173, 181-186 (2014).

10. Roberts C et al. N Engl J Med 375, 1142-1151 (2016).

Increasing evidence in the use of NHF for infants and children



A systematic search of available literature shows there are more than 220 peer-reviewed papers investigating the use of NHF therapy in infants and children.

Of these, 23 are randomized controlled trials (RCTs) - 10 of which compared NHF with standard oxygen therapy, nine with continuous positive airway pressure (CPAP) and four with alternative treatments. A further 10 are in the form of systematic reviews.



23 RCTs

- 10 compare NHF vs. standard oxygen therapy
- 9 compare NHF vs. CPAP*
- 4 compare NHF vs. alternative therapies

Plus a further 10 systematic reviews

1. McKiernan et al. J Pediatr (2010).

2. Schibler et al. Intensive Care Med (2011).

3. Wing et al. Pediatr Emerg Care (2012).

4. Milési et al. Intensive Care Med (2013).

5. Rubin et al. Pediatr Crit Care Med (2014).

6. Testa et al. Interact Cardiovasc Thorac Surg (2014).

7. Mayfield et al. J Paediatr Child Health (2014).

8. Pham et al. Pediatr Pulmonol (2015).

9. Milési et al. Intensive Care Med (2017).

10. Kepreotes et al. Lancet (2017).

11. Franklin et al. N Engl J Med (2018).


12. Ramnarayan et al. JAMA (2022).

13. Ramnarayan et al. JAMA (2022).



An RCT of high-flow oxygen therapy in infants with bronchiolitis.

This large multi-center RCT supports the early use of NHF in the ED and general care areas in young infants with bronchiolitis and may help reduce the escalation of therapy. This RCT used the F&P Airvo™ with an F&P Optiflow™ Junior interface.



Primary Outcome

- The early use of NHF in the ED and ward resulted in a significantly lower rate of therapy failure compared with standard oxygen therapy (12% vs. 23%, $p < 0.001$).

	Standard O ₂ therapy	Optiflow Junior NHF	
Therapy failure	167/733 (23%)	87/739 (12%)	$p < 0.001$
	↓		
Rescue NHF therapy failure	65/167 (39%)	↓	
	↓		
PICU admission	65/733 (9%)	87/739 (12%)	$p = 0.08$
	↓	↓	
Intubation	4/733 (0.5%)	8/739 (1%)	$p = 0.39$

Secondary Outcomes

- There were no significant differences between the secondary outcomes (PICU admissions, intubation rates and adverse events).
- 61% of patients who failed standard oxygen therapy were rescued by NHF and avoided PICU admission.



Current position of NHF in clinical practice

Putting NHF into practice

There are a number of possible pathways for the use of NHF for infants outside of the PICU.

Integration of NHF across the hospital environment may support standardization of care.



Humidified oxygen therapy

Heating and humidification of blended air and oxygen may avoid complications associated with cold and dry gas. It may also help assess severity of hypoxia and may help improve the standardization of equipment.

Early escalation to NHF

NHF has been shown to be an effective early escalation step following the use of standard oxygen therapy.

Primary NHF support

NHF (approx. 2 L/kg/min) can be used broadly as primary respiratory support to reduce therapy escalation compared with standard oxygen therapy.



PICU



ED




WARD

Integrating the use of NHF across the PICU, ED and ward may be associated with improved standardization of care. When used cohesively across the hospital, NHF may also contribute to a change in respiratory support practice, moving towards less invasive strategies. This leads to the potential for more patients to be managed in local hospitals and lower-acuity settings.¹⁻⁴

The current trends in literature suggest that NHF may have an increasing role across the hospital and a broad range of patient physiologies.

Range of patient physiologies: Other ED/general care PICU



1. Milési et al. Intensive Care Med (2013).
2. Rubin et al. Pediatr Crit Care Med (2014).

3. Pham et al. Pediatr Pulmonol (2015).
4. Franklin et al. N Engl J Med (2018).

Flow rates

Indicators summary

Flows

- 2 L/kg/min for infants up to 12 kg in weight has been shown to produce rapid improvement in reducing respiratory distress, and a reduced need for the escalation of therapy.
- Flow rates for those over 12 kg have been protocolized by the PARIS research group.¹

Weight

Up to 12 kg
13-15 kg
16-30 kg
31-50 kg
> 50 kg

Flow rate

2 L/kg/min
30 L/min
35 L/min
40 L/min
50 L/min

Literature suggests therapy outcome may be predicted within 60 minutes using clinical indicators.

Likely indicators for:

Within 60 minutes		Success	Caution
	Respiratory rate	Improvement ¹⁻⁴	No improvement ^{1,3,4}
	Heart rate	Improvement ^{1,3,4}	No improvement ^{3,4}
	Work of breathing	Improvement ¹	Currently no data
	Oxygen desaturation	Currently no data	No improvement ¹

The predictive quality of clinical indicators has not been assessed in definitive trials. The above information collates observational literature but does not overrule expert clinical judgement in patient management.

1. Franklin et al. N Eng J Med (2018).

2. Bressan et al. Eur J Pediatr (2013).
3. Canares et al. RI Med Jour (2014).
4. Mayfield et al. J Ped & Child Health (2014).

Optiflow Junior 2 interface product features

Wide flow range
(0.5 – 50 L/min)

Sizes to fit a wide
range of patients

Minimized condensate
and kinking with FlexiTube™

Soft, anatomically shaped
prong design

Easy application and
care with Wigglepads™ 2


Enhanced prong
retention with
Waveflex™ technology

Waveflex
TECHNOLOGY



F&P WigglewiNG

The F&P WigglewiNG™ can be used in conjunction with the Optiflow Junior 2/2+ to stabilize a nasogastric (NG) tube to the patient while maintaining the ability to remove or reposition the interface if necessary.



F&P Airvo 2

- Integrated flow generator delivers a wide flow range (2 to 60 L/min) – no wall air supply required.
- No separate temperature probes or heater-wire adapters required means that temperature can be accurately controlled to minimize condensation.
- Integrated O₂ mixing with an in-built O₂ sensor.
- Provides versatility, mobility and convenience.



Size and flow rates




L



Weight (kg)*	3	3.5	18	20
Correlated age**	37.5 wkGA	40 wkGA	4.9 yr	5.6 yr
Maximum flow rate	20 L/min			



XL



Weight (kg)*	5	7	25	30
Correlated age**	47.5 wkGA	4.7 mo	7.6 yr	9.5 yr
Maximum flow rate	25 L/min			



XXL



Weight (kg)*	8	12.5	30	40
Correlated age**	6.4 mo	2.2 yr	9.5 yr	12 yr
Maximum flow rate	50 L/min			

wkGA = weeks of gestation; mo = months; yr = years
* Weight data is based on F&P product validation studies.
** Age data is a correlation to weight data based on a combination of Fenton, WHO and CDC growth charts.

The above flow rates can be achieved on the F&P Airvo 2 platform. Flow rates achieved on other platforms may differ.

Collins CL, Holberton J, Barfield C, Davis PG. A randomized controlled trial to compare heated humidified high-flow nasal cannulae with nasal continuous positive airway pressure postextubation in premature infants. *J Pediatr* 162, 949-954.e1 (2013).

Collins CL, Barfield C, Horne R, Davis G. A comparison of nasal trauma in preterm infants extubated to either heated humidified high-flow nasal cannulae or nasal continuous positive airway pressure. *Eur J Pediatr* 173, 181-186 (2014).

de Klerk, A Humidified high-flow nasal cannula: is it the new and improved CPAP? *Adv Neonatal Care* 8, 98-106 (2008).

Franklin D et al. A randomized trial of high-flow oxygen therapy in infants with bronchiolitis. *N Engl J Med* 378, 1121-1131 (2018).

Hough J, Pham T, Schibler A. Physiologic effect of high-flow nasal cannula in infants with bronchiolitis. *Pediatr Crit Care Med*. 15, e214-219 (2014).

Kepreotes E et al. High-flow warm humidified oxygen versus standard low-flow nasal cannula oxygen for moderate bronchiolitis (HFWHO RCT) an open, phase 4, randomised controlled trial. *The Lancet* 389, 930-939 (2017).

Mayfield S, Bogossian F, O'Malley L, Schibler A. High-flow nasal cannula oxygen therapy for infants with bronchiolitis: pilot study (2014).

McKiernan C, Chua L, Visintainer P, Allen H. High-flow nasal cannulae therapy in infants with bronchiolitis. *The Journal of Pediatrics*, 156(4), 634-638 (2010).

Milési C et al. Is treatment with a high-flow nasal cannula effective in acute viral bronchiolitis? A physiologic study. *Intensive Care Med* 39, 1088-1094 (2013).

Milési C et al. High-flow nasal cannula (HFNC) versus nasal continuous positive airway pressure (nCPAP) for the initial respiratory management of acute viral bronchiolitis in young infants: a multicenter randomized controlled trial (TRAMONTANE study). *Intensive Care Med* 43, 209-216 (2017).

Pham T, O'Malley L, Mayfield S, Martin S, Schibler A. The effect of high-flow nasal cannula therapy on the work of breathing in infants with bronchiolitis. *Pediatr Pulmonol* 50, 713-720 (2015).

Ramnarayan P et al. Effect of High-Flow Nasal Cannula Therapy vs. Continuous Positive Airway Pressure Following Extubation on Liberation From Respiratory Support in Critically Ill Children: A Randomized Clinical Trial. *JAMA* 327(16), 1555-1565 (2022).

Ramnarayan P et al. Effect of High-Flow Nasal Cannula Therapy vs. Continuous Positive Airway Pressure Therapy on Liberation From Respiratory Support in Acutely Ill Children Admitted to Pediatric Critical Care Units: A Randomized Clinical Trial. *JAMA* 328(2), 162-172 (2022).

Roberts C et al. Nasal high-flow therapy for primary respiratory support in preterm infants. *N Engl J Med* 375, 1142-1151 (2016).

Rubin S et al. Effort of breathing in children receiving high-flow nasal cannula. *Pediatr Crit Care Med* 15, 1-6 (2014).

Saslow J et al. Work of breathing using high-flow nasal cannula in preterm infants. *J Perinatol* 26, 476-480 (2006).

Schibler A et al. Reduced intubation rates for infants after introduction of high-flow nasal prong oxygen delivery. *Intensive Care Med* 37, 847-852 (2011).

Sinha I, McBride A, Smith R, Fernandes R. CPAP and High-Flow Nasal Cannula Oxygen in Bronchiolitis. *Chest* 148, 810-823 (2015).

Testa G et al. Comparative evaluation of high-flow nasal cannula and conventional oxygen therapy in paediatric cardiac surgical patients: a randomized controlled trial. *Interact Cardiovasc Thorac Surg* 19, 456-61 (2014).

Wilkinson D, Andersen C, O'Donnell CPF, De Paoli AG, Manley BJ. High-flow nasal cannula for respiratory support in preterm infants. *Cochrane Database Syst Rev* 2, CD006405 (2016).

Wing R, James C, Maranda L, Armsby C. Use of high-flow nasal cannula support in the emergency department reduces the need for intubation in pediatric acute respiratory insufficiency. *Pediatr Emerg Care* 28, 1117-1123 (2012).